PROTAGONIST THERAPEUTICS, INC. (PTGX) Revenue 2017–2025
PROTAGONIST THERAPEUTICS, INC. (PTGX) annual revenue history from SEC filings — each fiscal year as reported, with year-over-year change.
$46.0MFY2025 · since FY2017: $20.1M → $46.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $46.0M | -89.4% |
| FY2024 | $434.4M | +624.1% |
| FY2023 | $60.0M | +125.7% |
| FY2022 | $26.6M | -2.8% |
| FY2021 | $27.4M | -4.4% |
| FY2020 | $28.6M | +12293.1% |
| FY2019 | $231,000 | -99.3% |
| FY2018 | $30.9M | +54.1% |
| FY2017 | $20.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More PTGX financial trends
PTGX Net incomePTGX Net marginPTGX Gross profitPTGX Gross marginPTGX Operating incomePTGX Operating marginPTGX Operating cash flowPTGX Free cash flowPTGX Capital expendituresPTGX Return on equityPTGX Stock buybacksPTGX Dividends paidPTGX Total assetsPTGX Total liabilitiesPTGX Shareholders’ equityPTGX overview →